Corcept Therapeutics (NASDAQ:CORT) shares plummeted 51.4% after the FDA rejected their New Drug Application for relacorilant, a hypertension treatment for hypercortisolism due to insufficient data. This unexpected setback raises concerns about the company’s growth prospects beyond Korlym, its main asset. The stock closed at $34.83, down 50.4% from the previous close. Corcept’s volatile stock has seen 25 significant moves in the past year, with recent drops due to FDA decisions and trial failures. The company is down 30.4% year-to-date and 69.6% below its 52-week high. Investors are now questioning the future of Corcept.

Read more at StockStory Inc.: Why Corcept (CORT) Shares Are Falling Today